|
|
供應(yīng) PF06463922原料 /1454846-35-5 |
規(guī) 格: |
見(jiàn)備注 |
價(jià) 格: |
600/元/公斤 |
數(shù) 量: |
100 公斤 |
交貨地: |
武漢 |
發(fā)布時(shí)間: |
2018-05-27 |
有效期: |
255天 |
備 注: |
PF06463922
CAS NO. 1454846-35-5
英文品名 PF-06463922
中文品名 PF-06463922
分子式 C21H19FN6O2
分子量 406.15
規(guī)格/純度 98%
供應(yīng)能力 can supply g scale
別名 PF 06463922;PF06463922
產(chǎn)品簡(jiǎn)述 PF-06463922 is a novel, orally available, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
詳細(xì)說(shuō)明 PF-06463922 demonstrates significant cell activity against ALK and a large set of ALK clinical mutations with IC50 ranging from 0.2 nM-77 nM. PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1(G2032R) mutation and the ROS1(G2026M) gatekeeper mutation. Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase. in vivo: PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1(G2032R) mutation. Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma. |
|
|